The CANVAS trial was supposed to provide definitive cardiovascular safety data for Janssen’s Invokana (canagliflozin) in type 2 diabetes – and while it has succeeded in this regard ...

This retrospective evaluation by Friedman et al. employed the new end point of clinical response at day 3 in evaluating the CANVAS 1 and 2 trials. This is the first analysis using the new US FDA ...